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Liver cirrhosis is the consequence of the wound-healing reaction subsequent to a chronic injury, 
which leads to a complete derangement of the normal hepatic lobular and vascular 
architecture. Cirrhosis is characterised by patterns of evolution depending on the causative 
agent and complex underlining mechanisms in which neo-angiogenesis and necro-inflammation 
play a key role. The importance of the different cell-type involved and of the extra cellular 
matrix (ECM) composition and the role of innate immunity, bacterial translocation and oxidative 
stress are also emerging. 
A variable degree of regression of fibrosis and even cirrhosis has been described, in 
experimental models, after the suspension of the liver disease causative agent. As some 
individual features influence the rate of fibrosis progression, genetic and epigenetic factors are 
likely to influence fibrosis regression. 
 
Key Messages 
There is increasing awareness that cirrhosis is not a static condition but a dynamic process. 
Current semi-quantitative scores and clinical classifications are inaccurate and unable to identify 
the different evolution phases of the advanced-stage chronic liver diseases (CLD). 
The increasing availability of effective aetiology-driven therapeutic options for CLD makes 
reversion of cirrhosis a more and more possible prospective. However, the removal of the 
causing agent, depending on the stage of the disease, does not necessarily eliminate the risk of 
disease progression, decompensation or development of hepatocellular carcinoma. Also, the 
non-invasive markers currently validated for the assessment of fibrosis are not suitable for an 
effective evaluation of fibrosis regression.  
 
Conclusions. 
There is a critical need of a system able to more accurately describe the dynamic development 
of cirrhosis and the impact of tissue fibrosis, neo-angiogenesis, necro-inflammation and 
attempted regeneration on its evolution. 
Effective treatment of CLD can lead to a variable degree of fibrosis regression. New markers 
able to evaluate this process will need to be detected and validated. 
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The set of morphologic alterations observed in the end stage of chronic liver diseases (CLD), 
characterized by a deranged hepatic angio-architecture of the liver parenchyma, are described 
as “cirrhosis”. The wound-healing reaction subsequent to a chronic injury leads to the formation 
of regenerative parenchymal nodules encapsulated and separated by fibrotic septa altering the 
normal lobular architecture [1]. Essential alterations of the vascular system in cirrhosis are the 
formation of intrahepatic shunts, derangement of the vascular network in portal tracts, 
capillarisation of sinusoids, perisinusoidal fibrosis, vascular thrombosis, under-perfusion of 
lobular parenchyma and resulting tissue hypoxia [2].  Overall, as just described, cirrhosis could 
be regarded as a vascular disease of the liver. Consequence of all these changes is the 
development of portal hypertension (PH) and its life-threatening complications. Furthermore, 
the constant attempt of hepatocyte regeneration occurring in a fibro-inflammatory tissue 
microenvironment is responsible of the potential occurrence of hepatocellular carcinoma (HCC).  
 
There is increasing awareness that the concept of liver cirrhosis as a static and irreversible end-
stage condition has became now inappropriate. Indeed, the advances in the understanding the 
mechanisms of chronic fibrogenic liver diseases have led to the conclusion that histological 
semi-quantitative scores, classically used in the attempt to define disease grade (necro-
inflammatory activity) and stage (tissue fibrosis) on biopsy specimens and the traditional 
classification of compensated and decompensated disease based on the degree of portal 
pressure and the occurrence of clinical complications, do not recapitulate and represent the 
complexity and the spectrum of different stages of advanced-stage CLD and their dynamic 
development [3]. 
Furthermore, it is now clear that the different types of CLD have characteristic patterns of 
fibrotic evolution, with distinctive predominant mechanisms and fibrogenic cell types [4]. 
In the era in which agents leading to a permanent suppression of hepatitis B virus (HBV) and 
new antivirals able to eradicate hepatitis C virus (HCV) in an extremely high percentage of cases 
have become real therapeutic options, regression of liver fibrosis and even of cirrhosis has 




MECHANISMS OF HEPATIC FIBROGENESIS AND THE DEVELOPMENT OF CIRRHOSIS. 
 
Chronic wound healing and fibrogenesis. The chronic wound-healing process triggered by 
reiterated liver tissue damage due to infective, metabolic, autoimmune, cholestatic or toxic 
causes activates a series of pro-fibrogenic mechanisms leading to a variable degree of 
necrosis/apoptosis of hepatic cells associated with inflammatory infiltration and the progressive 
accumulation of fibrillar extracellular matrix (ECM) [5,6].  
The continuous accumulation of fibrillar ECM is associated with its simultaneous degradation 
and remodeling, making fibrogenesis a potentially reversible dynamic process. However, with 
the advancement of CLD fibrosis becomes progressive and to a certain extent irreversible due to 
the exhaustion of the degradative machinery [5]. 
The wound-healing process is characterized by a cascade of biological events, which involve 
cells and soluble factors, aimed at resolving tissue injury (Figure 1). These events and effectors 
are disposed in a logical sequence with activation of the next step preceded by the resolution of 
the previous phase [7]. In the presence of a single tissue insult, this mechanism is highly 
effective, but in the context of a chronic liver injury, deposition of fibrillar matrix rather than 
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organized tissue regeneration becomes the best option in order to maintain tissue continuity, 
leading to progressive scarring of the tissue.  
The modification in ECM composition occurring in this process, with a predominance of collagen 
types I and III, has obvious physiological, biochemical and biomechanical implications. The 
accumulation of fibrillar ECM in the sinusoidal structures (capillarisation of sinusoids) alters the 
normal exchange of macromolecules and oxygen between hepatocytes and sinusoidal blood, 
induces profound changes in the expression of integrins and other cell adhesion molecules, acts 
as reservoir for pro-inflammatory and pro-fibrogenic mediators, and progressively increases 
tissue stiffness, a key profibrogenic mechanism leading to the modulation of several cellular 
function (growth, migration, gene expression) [5-7].  
Hepatic stellate cell (HSC) represent the main fibrogenic cell type in the liver. Presenting 
ultrastructural features of vascular pericytes, they have also a potential role in the regulation of 
sinusoidal blood flow. The process of HSC activation and phenotypical transformation into 
myofibroblasts, as well as their pro-fibrogenic role, have been extensively clarified. It is now 
evident that distinct ECM-producing cells, each with a distinct localization and a characteristic 
immunohistochemical and/or electron microscopic phenotype, are likely to contribute to liver 
fibrosis [5,6]. These include: fibroblasts and myofibroblasts of the portal tract, smooth muscle 
cells localized in vessel walls and myofibroblasts localized around the centrolobular vein. 
Myofibroblasts may also derive from a population of circulating fibroblast-like cells derived from 
bone marrow stem cells, called “fibrocytes”. The relative participation of these different ECM-
producing cells depends on the pattern of fibrosis evolution [8].  
Although cell biology of liver fibrosis has been mostly framed around activated HSC and more in 
general myofibroblast-like cells, other cells play a fundamental role in the fibrogenic process. In 
particular, macrophages are indispensable for both fibrosis progression and regression [9] and 
their activity is modulated by the direction of the cytokines and other soluble factors network 
towards progression or resolution. Platelet aggregation/degranulation, the activation of 
complement and of the coagulation cascade represent initial events of the wound-healing 
reaction. Accordingly, anticoagulants or antiplatelet agents have been shown to prevent fibrosis 
by acting on HSCs, in several animal models [10]. Cholangiocytes play a major role and 
contribute to the peribiliary fibrogenic process in CLD characterised by damage, proliferation 
and activation of the biliary epithelium. These cells express a wide range of profibrogenic 
molecules and, when activated, stimulate fibrogenic, apoptotic and proliferative response 
through an intense cross-talk with portal fibroblasts/myofibroblasts and HSC mediated by pro-
inflammatory and chemotactic cytokines such as IL-6, TNF-α, IL-8, and MCP-1  [11]. 
There is increasing evidence that the alterations of mechanisms of innate immunity occurring in 
systemic pro-inflammatory and pro-fibrogenic status and bacterial translocation affect CLD 
progression. In particular, a combination of dysbiosis and increased intestinal permeability, 
altered gut defences and reduced immunological surveillance leads to increased migration of 
bacteria or bacterial products from the intestinal lumen to mesenteric lymph-nodes or other 
extraintestinal sites [12]. Recently, the attention is focused on bacterial products named 
pathogen-associated molecular patterns (PAMPs): lipoproteins, bacterial DNA and double-
stranded RNA recognized by pattern recognition receptors (PRRs) present on a wide variety of 
cells [13]. The interaction between PAMPs and PRRs serves as a first-line defence during 
infection and activates numerous pro-inflammatory cytokine and chemokine responses. 
Fibroblasts, myofibroblasts and vascular pericytes express a variety of PRRs (including toll-like 
receptors -TLRs) which, when bound by their ligands, can promote the activation/differentiation 
of these cells into collagen-producing myofibroblasts and the establishment of a pro-
inflammatory/pro-fibrogenic condition in the portal circulation [14,15].  
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Neo-angiogenesis. In the last decades, increasing attention has been given to the key interplay 
between neo-angiogenesis and fibrogenesis and its role in the progression of CLD towards 
cirrhosis.  
Angiogenesis and up-regulation of vascular endothelium growth factor (VEGF) have been 
documented in experimental models of acute and chronic liver injury [16] as well as in 
specimens from human fibrotic/cirrhotic liver and hepatocellular carcinoma [17,18]. 
When activated by hypoxia occurring in the context of a chronic wound healing reaction, HCS 
represent a significant source of angiogenic cytokines and tend to acquire a generic “pro-
angiogenic” phenotype. They represent the target of the multiple actions of VEGF and 
angiopoietin 1 (Ang-1), including stimulation of proliferation, collagen type I synthesis and 
recruitment of other HSC [19]. 
The intrahepatic vascular remodelling occurring in CLD (capillarisation of sinusoids, 
development of intrahepatic shunts) leads to increased hepatic resistance, PH and decreased 
effective hepatocyte perfusion. The process of revascularisation is characterised by a chaotic 
pattern: many of the neoformed vessels have a “blind end” and only a minority of attempts 
result in portal-central anastomoses. These vascular structures follow irregular patterns and are 
surrounded by fibrotic tissue containing contractile cells (activated HSC, myofibroblasts). This 
leads to increased hepatic resistance and further reduction of the effective perfusion of 
hepatocytes, thus reiterating the hypoxic stimulus to angiogenesis and fibrogenesis [20]. 
 
 
Fibrosis and portal hypertension 
 
Portal hypertension (PH) is firstly the result of an increased intrahepatic resistance caused by 
architectural distortion (fibrous tissue, regenerative nodules), endothelial dysfunction leading to 
intrahepatic vasoconstriction and intrahepatic vascular shunts between afferent and efferent 
vessels of the liver [21,22]. Subsequently, portal hypertension is aggravated by an increase of 
portal and hepatic arterial blood flow. 
Hepatic venous pressure gradient (HVPG), an indirect measure of portal pressure, is the best 
predictor of the development of PH [23,24]. Progressive increases in HVPG correlate with 
increasing severity of liver disease: normal, chronic hepatitis, pre-cirrhosis and cirrhosis [25]. 
Despite the fact that histological features of disease progression within the stage of cirrhosis 
(since this is identified by the highest value of the currently used scoring systems) have not been 
traditionally linked to clinical outcomes, the analysis of some histologic features in cirrhotic liver 
biopsies may have important prognostic implications. For example, the thickness of fibrous 
septa correlates with HVPG and is an independent predictor of both clinically significant portal 
hypertension [26] and clinical decompensation [27].  
The recently introduced possibility to measure the quantity and the distribution of collagen as 
collagen proportional area (CPA), a new histological marker obtained by digital video imaging 
analysis, has allowed to better define the relationship between evolution of fibrosis and 
worsening of PH. Furthermore, scoring cirrhosis with a continuous scale may allow to predict 
relevant clinical outcomes [28,29].  
 
 
AETIOLOGY-DRIVEN FIBROGENETIC MECHANISMS AND PATTERNS  
 
In recent years, the increasing awareness that different CLD have distinct patterns of fibrotic 
development has led to the concept of “aetiology-driven cirrhosis” [30,31]. 
The different patterns of fibrogenic evolution are related to various factors, such as the 
topographic localization of tissue damage, the dynamics of the necro-inflammatory infiltrate, 
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the distribution of fibrosis, the relative concentration of pro-fibrogenic factors, the main pro-
fibrogenic mechanism(s) as well as the prevalent cellular effectors. Time to disease progression, 
distribution of fibrosis and onset/progression of PH are correlated and depend on the 
aetiological agent.  
The fibrotic pattern of chronic viral hepatitis is characterised by portal-central septa (likely the 
results of portal-central bridging necrosis), the presence of “interface” hepatitis and the 
development of portal-portal septa and septa ending blind in the parenchyma and a rapid 
derangement of the vascular connections with the portal system, which causes early portal 
hypertension. In biliary diseases, instead, the central vein and its connections with the portal 
tract are preserved until late stages and fibrosis. This is due to the co-proliferation of reactive 
bile ductules and periductular myofibroblast-like cells at the portal-parenchymal interface, 
which tends to follow a portal-to-portal direction, leading to the formation of portal-portal 
septa surrounding liver nodules and to the development of pre-sinusoidal resistance to portal 
flow. In alcoholic and metabolic liver diseases the deposition of fibrillar matrix is concentrated 
around the sinusoids (capillarisation) and around groups of hepatocytes (chicken-wire pattern). 
Finally, fibrosis secondary to venous outflow problems (e.g. chronic heart failure) is 
characterised by development of central-to-central septa and “reversed lobulation” (Table 1).  
Recent studies quantifying the amount of fibrosis present in cirrhotic livers of different 





REVERSIBILITY OF FIBROSIS AND CIRRHOSIS 
 
Evidence of fibrosis and even cirrhosis regression has been reported in CLD of different 
aetiologies, including viral hepatitis [33,34], autoimmune hepatitis [35], alcoholic and non-
alcoholic steatohepatitis [36,37], although, in most cases, the experienced liver pathologists 
who analysed these results have been in agreement only for a variable degree of fibrosis 
regression, but not for cirrhosis reversion [38,39]. Furthermore, it has to be underlined that the 
background scientific information is based on data obtained in experimental animal models, in 
which liver cirrhosis can be induced in only a few weeks and quickly reverted after the 
suspension of the exposure to the causative agent. This possibility is far from being 
substantiated in humans. Available evidence suggest that even extensive fibrosis regression is 
characterised by the persistence of veno-portal adhesions and “arterialized” sinusoids in the 
context of intrahepatic artero-venous shunts [40], raising serious doubts about a potential 
regression of the intrahepatic vasculature abnormalities in human cirrhotic liver. 
Critical events for the reversibility of fibrosis are the more or less rapid switch-off of the chronic 
wound-healing process characterized by the progressive reduction of necro-inflammation and 
the following reduction of the number of activated HSC trough pathways of apoptosis, 
senescence and reversion to quiescence. In addition, it has been demonstrated that 
macrophages play a key-role in the resolution of fibrosis, and data have raised the possibility 
that different classes of macrophages respectively responsible for fibrosis progression or 
regression, might exist [41].  
Cirrhosis has a very broad spectrum of variants (early, fully developed, “active” and “inactive”) 
and there is clear lack of an accurate scoring system able to identify the different evolution 
phases of the advanced-stage CLD and to better describe the dynamic development of the 
disease, its pathophysiology or the impact of tissue fibrosis, neo-angiogenesis, necro-
inflammation and attempted regeneration on the often life-threatening clinical manifestations.  
At the base of the problem is the fact that the staging of fibrosis is obtained using semi-
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quantitative scoring systems, in which cirrhosis is always represented by the highest score and 
considered as an end-stage of CLD [42]. On the other hand, the term “cirrhosis” identifies an 
advanced phase of CLD that per se is neither morphologically or clinically an end stage, 
particularly with the prospective of novel treatments able to stabilize or even reduce tissue 
fibrosis. The currently used classification of cirrhotic patients in 5 stages on the basis of the 
major clinical manifestations of their disease (stage 1: compensated with no esophageal varices; 
stage 2: compensated with esophageal varices, stage 3: ascites, stage 4: gastrointestinal 
bleeding, stage 5: infections and renal failure) is also inadequate in predicting evolution of 
disease and life-threatening events [2,3].  
It is expected that ability to revert and the relevance of different mechanisms involved in the 
regression of fibrosis may differ according to the effective stage of the disease (pre-cirrhosis, 
early cirrhosis, advanced/established cirrhosis).  In fact, several studies have demonstrated the 
capacity of the healing liver to reabsorb scar tissue following an effective causative treatment 
(i.e. sustained viral response, abstinence from alcohol etc.), while the possibility of established 
cirrhosis to reverse to normal is still quite doubtful [41].  Along these lines, it is clear that scar 
tissue in the liver of patients with a long-standing CLD is characterized by different stages of 
biochemical and biological evolution compared to that of a disease with recent onset. Within 
the same liver, in fact, there are different types of scar tissue with different potential and 
dynamics of reversibility once the etiological agent is eradicated and/or anti-fibrogenic strategy 
is established. 
Fibrotic deposition related to recent disease and characterized by the presence of thin reticulin 
fibres, often in the presence of a diffuse inflammatory infiltrate, is likely fully reversible, 
whereas long standing fibrosis, characterised by extensive collagen cross-linking by tissue 
transglutaminase, presence of elastin, dense acellular/paucicellular ECM and decreased 
expression and/or activity of specific metalloproteinases, is not [43]. Even more, it has been 
shown that long-term fibrogenesis occurring in human CLD is characterized by a progressive 
resistance to apoptosis of hepatic stellate cells/myofibroblasts with the consequent 
immovability of a critical mass of pro-fibrogenic cells [44].  
 
Portal hypertension reflects the histological changes typical of advanced stage liver disease 
(acellular fibrosis, extensive collagen crosslinking, elastin deposition) as well as the disease 
severity. When hepatic venous pressure gradient (HVPG) overcomes 12 mmHg, cirrhosis 
becomes a systemic disease, which severity and evolution are largely independent of liver tissue 
fibrosis. The absence of PH seems, then, to be a crucial determinant for the possibility of fibrosis 
regression in advanced-sage CLD [41]. 
 
The new interferon-free regimens for the treatment of HCV allow a sustained viral response 
(SVR) in almost 100% of the treated patients including patients with cirrhosis. Hence, viral 
eradication can be achieved also in advanced stages of the disease. SVR is likely to be followed 
by a decline of necro-inflammation and fibrosis progression, as well as by an improvement of PH 
and its clinical manifestations, risk of hepatocellular carcinoma (HCC), liver-related mortality and 
liver transplantation [45,46]. 
Similarly, NUC agents suppressing HBV DNA levels prevent disease progression and improve 
patients’ survival. Long-term treatment of HBV with NUC can result in histological reduction or 
stabilisation of liver fibrosis in most patients [47,48].  
However, obtaining a SVR in patients with HCV-related cirrhosis does not necessarily prevent 
the immediate risk of decompensation and/or of HCC. In fact, it has been reported that SVR 
significantly reduces the risk of decompensation and liver related death related only in patients 
categorised as “stage 1”, who do not present clinically significant PH. Furthermore, HCV 
clearance in compensated patients with a significant grade of PH does not lead to the abolition 
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of the risk of progression towards decompensation or to a significant reduction of PH [46]. In 
this context it is important to keep in mind that, despite the evidence of fibrosis (and even 
cirrhosis) regression in patients undergoing SVR, other processes such as ductular proliferation, 
loss of lobular zonation, portal inflammation and sinusoidal capillarisation may not regress 
following SVR [49]. 
It is likely that, beyond a certain level, the fibrogenic process may acquire a relative autonomy, 
leading to a further progression of the disease independently of the discontinuation of the 
causative agent and the consequent reduction of hepatocellular necrosis and inflammation. This 
may depend on the significant hyperplasia of activated HSC and myofibroblasts and the 
activation of antiapoptotic pathways in these cells [50], to the derangement of the hepatic 
angioarchitecture consequent to neoangiogenesis and the elevated tissue tension due to 
fibrotic tissue contraction, which are only minimally affected by the reduction of 
necroinflammation. In addition, the persistence of profibrogenic cofactors such as excessive 
alcohol intake and baseline metabolic factors is likely to negatively influence the extent and 
rapidity of fibrosis regression despite an effective etiological treatment.  
Since there is clear sufficient evidence that some individual factors influence the rate of fibrosis 
progression leading to the differentiation of patients in slow, intermediate and fast “fibrosers”, 
it is conceivable that the presence of genetic/epigenetics determinants affecting the rapidity of 





Thanks to the advancement in understanding the mechanisms leading to advanced stage CLD, it 
appears more and more clear that the disease is sustained by different prevalent mechanisms 
depending on the triggering aetiology, and that the word “cirrhosis”, traditionally implying a 
static and irreversible condition, is not reflecting the actual dynamicity of the underlining 
processes. 
Accordingly, there is an urgent need to redefine cirrhosis in order to better reflect its 
progression, reversibility, and prognosis, as well as its relationship to PH and fibrogenesis.  
This potentially calls for different morphological classifications, different non-invasive diagnostic 
and prognostic indicators, different aetiology-driven and/or antifibrotic therapies and, most 
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 Viral  
 Autoimmune 




- “Interface” hepatitis  
- Portal-portal septa  
- Septa ending blind in 
the parenchyma  
- Rapid derangement of 
the vascular 
connections with the 
portal system 















- Bile salt toxicity 
Portal-to-portal 
- Proliferation of 
reactive bile ductules 
and periductular 
myofibroblast-like 
cells at the portal-
parenchymal 
interface  
- Portal-portal septa  
- Development of pre-
sinusoidal resistance 





 Alcoholic  
 Metabolic  
(- NASH 
 - Wilson 
disease 



















 Chronic heart 
failure 
- Venous outflow 
problems Central-to-
central 
- “Reversed lobulation” - HSC Early 
 
PH: portal hypertension. HSC: hepatic stellate cells. NASH: non-alcoholic steatohepatitis. 
 
 
